Nanoform Interim Report January – June 2021
Company Announcement Nanoform Finland Plc August 26, 2021 08:10 a.m. Finnish time / 07:10 a.m. Swedish time Nanoform Interim Report January – June 2021 The strong momentum continues: Additional line capacity, more projects, new clients, the number of employees crosses 100, while the gross margin forcefully breaks through 90 per cent. Letter of intent signed for the development, manufacturing, and commercialization of a by nanoforming improved version of a current blockbuster drug. Q2/2021 key financials: - Revenue came in at EUR 0.55 million, up 185% compared with EUR 0.